MetaCap

Mustang Bio (MBIO) vs Traws Pharma (TRAW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Traws Pharma is the larger company by market cap ($2.7 million vs $2.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBIO-21.35%TRAW-63.47%
+6%-30%-67%
Oct 7, 20261 yearNov 20, 2026
MBIO-11.50%TRAW-60.69%
+9%-28%-64%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBIO versus TRAW key metrics
MetricMBIOTRAW
Share price$0.3541$0.175
Market cap$2.69M$2.69M
1-day change-4.30%-23.91%
EPS (TTM)$-0.51$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.79M
Revenue growth (YoY)—+1134.51%
Net income (latest FY)$-1.92M$9.17M
Operating margin—-640.68%
Net margin—328.67%
52-week high$1.43$3.23
52-week low$0.35$0.1698
Distance from 52-week high-75.24%-94.58%
Analyst consensus—none
Avg. price target upside—+471.43%
Average volume33.87K610.04K
Shares outstanding6.74M15.37M
Employees44
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Mustang Bio

MBIO stock →

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Traws Pharma

TRAW stock →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

MBIO vs TRAW FAQ

Which is bigger, Mustang Bio or Traws Pharma?

Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.69M for Mustang Bio (MBIO).

Are Mustang Bio and Traws Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons